Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Regenerating nerve tissue in spinal cord injuries

CHICAGO, Aug. 13, 2015 /PRNewswire/ — Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach. The therapy uses a population of cells derived […]

Read More »

Testing for more breast cancer genes offers useful information

When the results of a test wouldn’t change how doctors manage a patient’s care, most say it’s not worth doing. But new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds. The BRCA1 and BRCA2 gene mutations put women […]

Read More »

Women tend to stick with IUDs over long term

Women who choose IUDs for long-acting reversible contraception (LARC) tend to keep the devices over several years, suggesting they’re satisfied with that method, according to a new U.S. study. Women in the St. Louis, Missouri area who chose long-acting methods like an intrauterine device (IUD) or an implant that’s placed under the skin were more […]

Read More »

For fat loss, calories may matter more than fat or carbs

Want to lose body fat? At least initially, a diet low in fat may be better than one that limits carbohydrates, a U.S. study suggests. To test the effects of cutting fat or carbs head-to-head, researchers put 19 obese adults in the hospital twice, each time reducing their calorie intake by about 30 percent and […]

Read More »

Genentech Ramps Up Partnerships for Next-Gen Cancer Drugs

Genentech (RHHBY) has partnered with several pharmaceutical companies, including AbbVie (ABBV), Clovis Oncology (CLVS) and Immune Design Corp. (IMDZ), as it ramps up its oncology pipeline. On Wednesday, Genentech and its partner AbbVie announced its promising experimental leukemia drug Venetoclax yielded a positive result in reducing the number of cancer cells in patients with previously […]

Read More »

GSK hopes big clinical trial can breath new life into lung drug

GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result. Data from the so-called SUMMIT study, designed to show GSK’s Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years […]

Read More »

Desperately Seeking Price Reform: The Pharmaceutical Industry Needs To Change Its Ways

By David Beier, John Osborn and Merv Turner A familiar trope employed at the climax of movie thrillers is the zombie who returns from the dead to devour the brains of the living. The biopharmaceutical industry may feel as if it is living in its very own horror show as zombies take the form of […]

Read More »

Rumors Heat Up (Again) That Pfizer Will Buy GlaxoSmithKline

Ever since Pfizer Inc. (PFE)’s $119 billion bid for UK-based AstraZeneca PLC (AZN) collapsed in May 2014, analysts have speculated on who Pfizer might buy. For several months now, heating up at the moment, those rumors have been that Pfizer might take a shot at UK-based GlaxoSmithKline (GSK).   The speculation over a Pfizer-GSK deal […]

Read More »

Roche Grabs Superbug Diagnostics Firm GeneWeave Biosciences in $425 Million Deal

Roche Acquires Geneweave To Strengthen Offerings In Microbiology Diagnostics GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed a definitive agreement to acquire GeneWEAVE BioSciences, Inc. (GeneWEAVE), a privately held company focused on innovative, clinical microbiology diagnostics solutions based in Los Gatos, […]

Read More »

FDA Pushes Back Review Date on Bristol-Myers Squibb’s Key Melanoma Drug Opdivo

August 13, 2015By Mark Terry, Breaking News Staff Bristol-Myers Squibb Company (BMY) announced yesterday that after delivering additional clinical trial data regarding expanded use of cancer drug Opdivo, the U.S. Food and Drug Administration (FDA) had delayed the decision date in order to evaluate the new data. Originally the supplemental Biologics License Application (sBLA) […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom